Modern Long. The shares of pharmaceutical companies generally behave like ordinary shares after the positive news has been publicly accepted as a matter of fact. However, just as good quarterly results are driving growth for the equity sector in general, unexpected “positive news” is driving drivers for pharmaceutical companies. One of these we witnessed today after the US government’s health authority recommended suspending the distribution of J&J’s Covid-19 vaccine for at least a few days due to the rare occurrence of blood clots. Johnson & Johnson is now actively working to suspend distribution within the European Union. It is therefore possible that a “blank space” will be created on the market, which will be able to be used by competing companies, see Moderna or BioNTech, where the distribution and use of the vaccine proceeds smoothly.